natgillin/translations-raw huggingface dataset:
Decrease in ANC was not associated with higher incidence of infections, including serious infections.
Zmanjšanja AŠN ni spremljala večja pojavnost okužb, vključno z resnimi okužbami.
Table 3: Clinical Response at Weeks 12, 24, and 52 in Placebo-Controlled Studies, MOBILITY and TARGET
Preglednica 3: Klinični odziv 12., 24. in 52. teden v študijah MOBILITY in TARGET, kontroliranih s placebom
Placebo-controlled studies
S placebom kontrolirane študije
Treatment with immunosuppressants may result in an increased risk of malignancies.
Zdravljenje z imunosupresivnimi zdravili lahko poveča tveganje za maligne bolezni.
• warfarin, used to prevent blood clots.
• varfarin, ki se uporablja za preprečevanje krvnih strdkov.
These responses persisted through 3 years of therapy in an open-label extension study.
Ti odzivi so trajali ves čas 3-letnega zdravljenja v podaljšani študiji z načrtom odprtega zdravljenja.
Patients should be advised to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction.
Bolnikom je treba naročiti, naj nemudoma poiščejo zdravniško pomoč, če se jim pojavi kakšen simptom preobčutljivostne reakcije.
• statins, used to reduce cholesterol level
• statine, ki se uporabljajo za znižanje koncentracije holesterola,
• lived in or travelled to areas of endemic tuberculosis or endemic mycoses.
• so živeli na območju endemične tuberkuloze ali endemičnih mikoz ali so potovali na takšna območja.
• Check the expiry date (EXP), this is shown on the side of the pens.
• Preverite datum izteka roka uporabnosti (EXP), to je prikazano na strani peresnikov.
If somebody else gives you the injection, you can also use the outer area of the upper arm.
Če vam zdravilo injicira nekdo drug, lahko uporabi tudi zunanji del nadlakta.
When clinically indicated, consider other liver function tests such as bilirubin.
Če je klinično indicirano, pridejo v poštev drugi testi jetrne funkcije, na primer bilirubin.
Component (range)
Komponenta (razpon)
ANC greater than 1
AŠN več kot 1
Kevzara can affect the way some medicines work: this means the dose of other medicines may need changing.
Zdravilo Kevzara lahko vpliva na delovanje nekaterih zdravil: to pomeni, da bo morda treba spremeniti odmerek drugih zdravil.
These parallel elimination pathways result in an initial half-life of 8 to 10 days, and at steady-state an effective halflife of 21 days is estimated.
Rezultat teh vzporednih poti izločanja je začetni razpolovni čas od 8 do 10 dni in efektivni razpolovni čas v stanju dinamičnega ravnovesja, ki je ocenjen na 21 dni.
The safety of Kevzara in combination with DMARDs was evaluated based on data from seven clinical studies, of which two were placebo-controlled, consisting of 2887 patients (long- term safety population).
Varnost zdravila Kevzara v kombinaciji z DMARD so ocenili na podlagi podatkov iz sedmih kliničnih študij, od katerih sta bili dve kontrolirani s placebom; te študije so zajele 2887 bolnikov (dolgoročna varnostna populacija).
In addition to this leaflet, you will be given a patient alert card, which contains important safety information that you need before and during treatment with Kevzara.
Poleg navodila za uporabo boste prejeli opozorilno kartico, ki vsebuje pomembne varnostne informacije, ki jih potrebujete pred in med zdravljenjem z Kevzara.
Two patients on Kevzara (0.2%) discontinued treatment due to injection site reactions.
Dva bolnika na zdravilu Kevzara (0,2 %) sta zdravljenje prenehala zaradi reakcij na mestu injiciranja.
• then inject your next dose at your regular time.
• nato injicirajte naslednji odmerek ob običajnem času.
For these reasons, comparison of the incidence of antibodies to Kevzara with the incidence of antibodies to other products may be misleading.
Zato je lahko primerjava pojavnosti protiteles proti zdravilu Kevzara s pojavnostjo protiteles proti drugim zdravilom lahko zavajajoča.
These injection site reactions (including erythema and pruritus) were mild in severity for the majority of patients.
Te reakcije na mestu injiciranja (vključno z rdečino in srbenjem) so bile pri večini bolnikov blage.
RA patients have an increased risk for cardiovascular disorders and risk factors (e.g. hypertension, hyperlipidaemia) should be managed as part of usual standard of care.
Bolniki z RA imajo večje tveganje za srčno-žilne bolezni in dejavnike tveganja za slednje (npr. hipertenzijo, hiperlipidemijo) je treba obvladovati v okviru običajne standardne zdravstvene oskrbe.
• You will need an alcohol wipe, a cotton ball or gauze, and a puncture-resistant container.
• Potrebovali boste alkoholni listič, kosem vate ali zloženec iz gaze in vsebnik za ostre odpadke.
The efficacy of sarilumab with concomitant DMARDs on inhibition of radiographic progression that was assessed as part of the primary endpoints at Week 52 in MOBILITY was sustained up to three years from the start of treatment.
Učinkovitost sarilumaba s sočasnimi DMARD za zavrtje rentgenografskega napredovanja, ocenjeno kot del primarnih opazovanih dogodkov po 52 tednih študije MOBILITY, se je ohranilo do tri leta od začetka zdravljenja.
No cases of Hepatitis B reactivation were reported in the clinical studies; however patients who were at risk for reactivation were excluded.
V kliničnih študijah niso zabeležili reaktivacije hepatitisa B, vendar pa je treba pri tem upoštevati, da bolniki s tveganjem za reaktivacijo v te študije niso bili vključeni.
Prepare the injection site.
Pripravite mesto za injiciranje.
Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity with Kevzara.
Imunogenost Tako kot pri vseh terapevtskih beljakovinah tudi pri zdravilu Kevzara obstaja možnost imunogenosti.
What you need to know before you use Kevzara 3.
Kaj morate vedeti, preden boste uporabili zdravilo Kevzara 3.
In particular, do not use Kevzara and tell your doctor or pharmacist if you are using:
Še zlasti ne uporabite zdravila Kevzara ter zdravnika ali farmacevta obvestite, če uporabljate:
• Your doctor, pharmacist, or nurse will show you how to inject Kevzara.
• Zdravnik, farmacevt ali medicinska sestra vam bo pokazal(a), kako injicirati zdravilo Kevzara.
The most commonly reported infections (5% to 7% of patients) were upper respiratory tract infections, urinary tract infections, and nasopharyngitis.
Najpogosteje zabeležene okužbe (pri 5 do 7 % bolnikov) so bile okužbe zgornjih dihal, okužbe sečil in nazofaringitis.
Hypersensitivity to the active substance or any of the excipients listed in section 6.1.
Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
• you have had viral hepatitis or other liver disease.
• ste imeli virusni hepatitis ali kakšno drugo bolezen jeter.
• That Kevzara treatment may increase the risks of serious infections, neutropenia and intestinal perforation.
• Da lahko zdravljenje z zdravilom Kevzara poveča tveganje za resne okužbe, nevtropenijo in perforacijo črevesa.
Kevzara is not recommended in children and adolescents under 18 years of age.
Zdravilo Kevzara ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
• high cholesterol, high triglycerides shown by blood tests
• visok holesterol, visoki trigliceridi (oboje se pokaže na preiskavi krvi)
ANC less than 0.5
AŠN manj kot 0,5
Treatment with sarilumab resulted in decreases in fibrinogen and serum amyloid A, and increases in haemoglobin and serum albumin.
Zdravljenje s sarilumabom je povzročilo znižanje fibrinogena in serumskega amiloida A ter zvišanje hemoglobina in serumskega albumina.
Sarilumab is eliminated by parallel linear and non-linear pathways.
Sarilumab se izloča vzporedno po linearni in nelinearni poti.
• Educate patients on signs or symptoms that could represent serious infections or gastrointestinal perforations to seek for medical attention immediately.
• Seznanitev bolnikov z znaki in simptomi, ki bi lahko pomenili resne okužbe ali perforacijo črevesa, z navodilom, da morajo v takšnem primeru nemudoma poiskati zdravniško pomoč.
• oral contraceptives
• peroralne kontraceptive,
The most frequently observed serious infections included pneumonia and cellulitis.
Najpogosteje zabeleženi resni okužbi sta bili pljučnica in celulitis.
If it has been 4 days or more since the missed dose, the subsequent dose should be administered at the next regularly scheduled time, the dose should not be doubled.
Če so od izpuščenega odmerka minili 4 dnevi ali več, je treba naslednji odmerek uporabiti ob naslednjem redno predvidenem času; odmerka se ne sme podvojiti.
Do not get rid of any air bubbles in the syringe.
Ne odstranjujte morebitnih zračnih mehurčkov v brizgi.
If it has been 4 days or more, inject the next dose at your regular time.
Če so od izpuščenega odmerka minili 4 dnevi ali več, injicirajte naslednji odmerek ob običajnem času.
Fertility studies conducted in male and female mice using a murine surrogate antibody against mouse IL-6Rα showed no impairment of fertility.
Študije plodnosti, izvedene pri mišjih samcih in samicah z uporabo mišjega nadomestnega telesa proti mišjemu IL-6Rα, niso pokazale okvare plodnosti.
As a monoclonal antibody sarilumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.
Ker je sarilumab monoklonsko protitelo, je mogoče pričakovati, da se razgradi v majhne peptide in aminokisline po kataboličnih poteh, enako kot endogeni IgG.
The excretion of sarilumab in Cynomolgus monkey's milk has not been studied.
Izločanja sarilumaba v mleko pri opicah Cynomolgus niso raziskali.
• Based on the pharmacodynamics of the changes in ANC, use results obtained at the end of the dosing interval when considering dose modification (see section 5.1).
• Na osnovi farmakodinamike sprememb AŠN, pri prilagajanju odmerka uporabite izvide, dobljene ob koncu odmernega intervala (glejte poglavje 5.3).
Do not use if the window is solid yellow.
Ne uporabljate, če je okence rumeno.
Major clinical response¶
Večji klinični odziv¶
The results of the components of the ACR response criteria at Week 24 for MOBILITY and TARGET are shown in Table 4.
Rezultati komponent meril odziva ACR po 24 tednih v študijah MOBILITY in TARGET so prikazani v preglednici 4.
• Carefully follow the “Instructions for Use” provided in the carton.
• Natančno upoštevajte "Navodila za uporabo", priložena v škatli.
Low Absolute Neutrophil Count (see section 5.1) Lab Value (cells x 109/L) Recommendation
Majhno absolutno število nevtrofilcev (glejte poglavje 5.1) Laboratorijska vrednost (celic x 109/l)
Put the yellow needle cover on your skin at roughly a 90° angle.
Namestite rumeni pokrovček igle ob kožo pod kotom približno 90 stopinj.
Patients with latent or active tuberculosis should be treated with standard antimycobacterial therapy before initiating Kevzara.
Bolnike z latentno ali aktivno tuberkulozo je treba pred uvedbo zdravila Kevzara zdraviti s standardnim protimikobakterijskim zdravljenjem.
It is unknown whether sarilumab is excreted in human milk or absorbed systemically after ingestion.
Ni znano, ali se sarilumab pri človeku izloča v materinem mleku in ali se po zaužitju sistemsko absorbira.
Increased frequency and magnitude of these elevations were observed when potentially hepatotoxic medicinal products (e.g., MTX) were used in combination with Kevzara.
Večjo pogostnost in velikost teh zvišanj so opažali, če so bila v kombinaciji z zdravilom Kevzara uporabljena potencialno hepatotoksična zdravila (npr. metotreksat).
What Kevzara is and what it is used for 2.
Kaj je zdravilo Kevzara in za kaj ga uporabljamo 2.
Do not dispose of your used puncture-resistant container in your household waste unless your local guidelines permit this.
Ne zavrzite uporabljenega vsebnika za ostre odpadke med gospodinjske odpadke (razen če to dovoljujejo vaši lokalni predpisi).
Various in vitro and limited in vivo human studies have shown that cytokines and cytokine modulators can influence the expression and activity of specific cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) and therefore have the potential to alter the pharmacokinetics of concomitantly administered medicinal products that are substrates of these enzymes.
Različne humane študije in vitro in maloštevilne in vivo so pokazale, da lahko citokini in citokinski modulatorji vplivajo na izraženost in aktivnost specifičnih encimov citokroma P450 (CYP) (CYP1A2, CYP2C9, CYP2C19 in CYP3A4) in tako lahko spremenijo farmakokinetiko sočasno uporabljenih zdravil, ki so substrati teh encimov.
Kevzara can lower your body's ability to fight infection: this means it can make you more likely to get infections or make your infection worse.
Zdravilo Kevzara lahko zmanjša sposobnost telesa za premagovanje okužb: to pomeni, da lahko poveča vašo dovzetnost za okužbe, ali vam okužbo poslabša.
However, if you are feeling tired or unwell after you use Kevzara, you should not drive or use machines.
Toda če se po uporabi zdravila počutite utrujeni ali se ne počutite dobro, ne upravljajte vozil in strojev.
Do not use the syringe if the date has passed.
Ne uporabite brizge, če je ta datum že mimo.
The recommended dose is one 200 mg injection every two weeks.
Priporočeni odmerek je ena injekcija 200 mg na dva tedna.
Do not heat the pen; let it warm up on its own.
Ne segrevajte peresnika: pustite, da se ogreje sam.
Do not stop using Kevzara without talking to your doctor.
Ne prenehajte uporabljati zdravila Kevzara, ne da bi se prej posvetovali z zdravnikom.
(see section 5.2).Interaction of sarilumab with substrates of other CYPs (CYP2C9, CYP 2C19, CYP2D6) has not been studied.
Medsebojnih delovanj sarilumaba s substrati drugih CYP (CYP2C9, CYP 2C19, CYP2D6) niso raziskali.
The European Medicines Agency has deferred the obligation to submit the results of studies with Kevzara (sarilumab) in one or more subsets of the paediatric population in chronic idiopathic arthritis (including rheumatoid arthritis, spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis) (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Kevzara (sarilumab) za eno ali več podskupin pediatrične populacije pri kroničnem idiopatičnem artritisu (vključno z revmatoidnim artritisom, spondilartritisom, psoriatičnim artritisom in juvenilnim idiopatičnim artritisom) (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
MOBILITY evaluated 1197 patients with RA who had inadequate clinical response to MTX.
Študija MOBILITY je ocenila 1197 bolnikov z RA, ki se niso klinično ustrezno odzvali na metotreksat.
Select the injection site.
Izberite mesto injiciranja.
Elderly: No dose adjustment is required in patients over 65 years of age (see section 4.4).
Starejše osebe: Bolnikom, starejšim od 65 let, odmerka ni treba prilagoditi (glejte poglavje 4.4).
Blood and Lymphatic System Disorders
Bolezni krvi in limfatičnega sistema
Treatment should be started by a doctor experienced in the diagnosis and treatment of rheumatoid arthritis.
Zdravljenje mora uvesti zdravnik, ki ima izkušnje v diagnosticiranju in zdravljenju revmatoidnega artritisa.
Monoclonal antibodies are not eliminated via renal or hepatic pathways.
Monoklonska protitelesa se ne odstranijo po ledvični ali jetrni poti.
• inject your missed dose as soon as you can.
• izpuščeni odmerek injicirajte čim prej.
Current dose of Kevzara should be maintained.
Trenutni odmerek zdravila Kevzara je treba ohraniti.
Lipid parameters (LDL, HDL, and triglycerides) were first assessed at 4 weeks following initiation of Kevzara+ DMARDs in the placebo-controlled population.
Lipidi Vrednosti lipidov (LDL, HDL in trigliceridov) so najprej ocenili 4 tedne po uvedbi kombinacije zdravila Kevzara + DMARD v populaciji, kontrolirani s placebom.
• cold sores (“oral herpes”)
• oralni herpes ("ocvirki")
There are no or limited amount of data from the use of sarilumab in pregnant women.
Podatkov o uporabi sarilumaba pri nosečnicah ni oziroma so omejeni.
Patients receiving Kevzara 200 mg + DMARDs reported greater improvement relative to placebo in the domains of Physical Functioning, Role Physical, Bodily Pain, General Health Perception, Vitality, Social Functioning, and Mental Health.
Bolniki, ki so prejemali 200 mg zdravila Kevzara + DMARD, so v primerjavi s placebom navajali večje izboljšanje na področjih telesnega delovanja, telesne vloge, telesnih bolečin, splošnega dojemanja zdravja, vitalnosti, socialnega delovanja in mentalnega zdravja.
Sanofi Winthrop Industrie 1051 Boulevard Industriel 76580 Le Trait, France
Sanofi Winthrop Industrie 1051 Boulevard Industriel 76580 Le Trait, Francija
Figure 1: Percent of ACR20 Response by Visit for MOBILITY
Slika 1: Odstotek odziva ACR20 po obisku v študiji MOBILITY
The total content (1.14 ml) of the pre-filled syringe/pre-filled pen should be administered as a subcutaneous injection.
Celotno vsebino (1,14 ml) napolnjene injekcijske brizge/napolnjenega injekcijskega peresnika je treba uporabiti v subkutani injekciji.
After removing the pre-filled syringe/pre-filled pen from the refrigerator, it should be allowed to reach room temperature (<25°C) before injecting Kevzara.
Potem, ko vzamemo napolnjena injekcijska brizga/napolnjen injekcijski peresnik iz hladilnika, je treba pustiti da pred injiciranjem zdravila Kevzara doseže sobno temperaturo (< 25 °C).
When considering anti-tuberculosis therapy, consultation with a physician with expertise in tuberculosis may be appropriate.
Kadar razmišljate o protituberkuloznem zdravljenju, premislite o posvetu z zdravnikom, ki ima izkušnje na področju tuberkuloze.
TARGET evaluated 546 patients with RA who had an inadequate clinical response or were intolerant to one or more TNF-α antagonists.
Študija TARGET je ocenila 546 bolnikov z RA, ki se niso ustrezno klinično odzvali na enega ali več antagonistov TNF-α ali teh zdravil niso prenašali.
Twist or pull off the orange cap.
Zavrtite ali snemite oranžen pokrovček.
Cases of opportunistic infection have been reported (see section 4.4).
Poročali so o primerih oportunističnih okužb (glejte poglavje 4.4).
The symptoms may include fever, sweats, or chills.
Med simptomi so lahko zvišana telesna temperatura, znojenje ali mrzlica.
IL-6 is involved in diverse physiological processes such as migration and activation of T-cells, B-cells, monocytes, and osteoclasts leading to systemic inflammation, synovial inflammation, and bone erosion in patients with RA.
IL-6 je vpleten v različna fiziološka dogajanja, npr. migracijo in aktivacijo celic T, celic B, monocitov in osteoklastov, in povzroča sistemsko vnetje, vnetje sinovije in erozijo kosti pri bolnikih z RA.
• you have recently had any vaccination or are going to have a vaccination.
• ste nedavno opravili kakšno cepljenje ali imate predvideno kakšno cepljenje.
After multiple dosing of 150 to 200 mg every two weeks, steady state was reached in 12 to 16 weeks with a 2- to 3-fold accumulation compared to single dose exposure.
Po večkratnem odmerjanju od 150 do 200 mg na dva tedna je bilo stanje dinamičnega ravnovesja doseženo v 12 do 16 tednih z 2- do 3-kratnim kopičenjem v primerjavi z izpostavljenostjo po enkratnem odmerku.
Upon initiation or discontinuation of Kevzara in patients being treated with CYP substrate medicinal products, therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., theophylline) should be performed and the individual dose of the medicinal product should be adjusted as needed.
Po uvedbi ali prenehanju uporabe zdravila Kevzara pri bolnikih, ki prejemajo zdravila, ki so substrati CYP, je treba spremljati terapevtski učinek (npr. pri varfarinu) ali koncentracije zdravila (npr. teofilina) in individualno prilagoditi odmerek zdravila, kot je potrebno.
Do not inject a double dose to make up for a forgotten injection.
Ne injicirajte dvojnega odmerka, če ste pozabili injicirati prejšnjega.
If you are using any of the following medicines, tell your doctor or pharmacist before using Kevzara:
Če uporabljate katero od naslednjih zdravil, o tem obvestite zdravnika ali farmacevta, preden uporabite zdravilo Kevzara:
• a history of serious or opportunistic infections;
• kronične ali ponavljajoče se okužbe, • anamnezo resnih ali oportunističnih okužb,
Most patients who developed gastrointestinal perforations were taking concomitant nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, or methotrexate.
Večina bolnikov, ki se jim je pojavila perforacija prebavil, so sočasno jemali nesteroidna protivnetna zdravila (NSAR), kortikosteroide ali metotreksat.
In both MOBILITY and TARGET, higher ACR20 response rates were observed within 2 weeks compared to placebo and were maintained for the duration of the studies (see Figures 1 and 2).
V obeh študijah, MOBILITY in TARGET, so po 2 tednih opažali večji delež odziva ACR20 kot s placebom in to se je ohranilo med celotnim trajanjem študij (glejte sliki 1 in 2).
The interval between live vaccinations and initiation of Kevzara therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents (see section 4.5).
Presledek med uporabo živih cepiv in uvedbo zdravila Kevzara mora biti v skladu s trenutnimi smernicami za cepljenja, ki zadevajo imunosupresivna zdravila (glejte poglavje 4.5).
Talk to your doctor, pharmacist, or nurse if:
Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro, če:
Consider anti-tuberculosis therapy prior to initiation of Kevzara in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.
Pred uvedbo zdravila Kevzara razmislite o protituberkuloznem zdravljenju pri bolnikih, ki so imeli v preteklosti latentno ali aktivno tuberkulozo, a pri katerih ni mogoče potrditi ustrezno opravljenega zdravljenja, ter pri bolnikih, ki imajo negativen izvid testiranja za latentno tuberkulozo, vendar imajo dejavnike tveganja za tuberkulozno okužbo.
Contents of the pack and other information What Kevzara contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Kevzara
The MAH shall ensure that in each Member State where Kevzara is marketed, all healthcare professionals who are expected to prescribe Kevzara have access to the patient alert card.
Imetnik dovoljenja za promet bo zagotovil, da bodo v vseh državah članicah, kjer bo zdravilo Kevzara na trgu, vsi zdravniki, ki bodo predvidoma predpisovali zdravilo Kevzara, imeli dostop do opozorilnih kartic za bolnika.
A patient who develops an infection during treatment with Kevzara should also undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored.
Če se bolniku med zdravljenjem z zdravilom Kevzara pojavi okužba, je treba tudi takoj opraviti celotno diagnostično testiranje, primerno za imunsko oslabele bolnike; uvesti je treba ustrezno antimikrobno zdravljenje in bolnika skrbno nadzirati.
Blockade of IL-6 signalling by IL-6Rα antagonists such as sarilumab might reverse the inhibitory effect of IL-6 and restore CYP activity, leading to altered medicinal products concentrations.
Blokada signalizacije IL-6 z antagonisti IL-6Rα, kakršen je sarilumab, lahko preobrne zaviralni učinek IL-6 in obnovi aktivnost CYP ter tako povzroči spremembo koncentracije zdravil.
• A warning message for HCPs treating the patient at any time, including in conditions of emergency, that the patient is using Kevzara.
• Opozorilo zdravnikom, ki kadar koli zdravijo bolnika - to velja tudi za primere nujnega zdravljenja - da bolnik uporablja zdravilo Kevzara.
Also some other medicines can affect the way Kevzara works.
Tudi nekatera druga zdravila lahko vplivajo na delovanje zdravila Kevzara.
The use of Kevzara is not expected to affect your ability to drive or use machines.
Ni pričakovati, da bi zdravilo Kevzara vplivalo na vašo sposobnost upravljanja vozil ali strojev.
• Hold the syringe in the middle of the syringe body with the needle pointing away from you.
• Primite brizgo na sredini telesa brizge in tako, da bo igla obrnjena proč od vas.